Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 76 | 2021 | 262 | 10.970 |
Why?
|
| Anti-Asthmatic Agents | 12 | 2020 | 37 | 2.600 |
Why?
|
| Adrenal Cortex Hormones | 14 | 2021 | 115 | 2.000 |
Why?
|
| Severity of Illness Index | 28 | 2021 | 851 | 1.910 |
Why?
|
| Phenotype | 24 | 2021 | 619 | 1.820 |
Why?
|
| Sputum | 9 | 2021 | 17 | 1.340 |
Why?
|
| Bronchodilator Agents | 12 | 2021 | 34 | 1.240 |
Why?
|
| Lung | 12 | 2021 | 264 | 1.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 116 | 1.010 |
Why?
|
| Bronchoscopy | 4 | 2019 | 54 | 0.980 |
Why?
|
| Eosinophils | 10 | 2021 | 31 | 0.960 |
Why?
|
| Forced Expiratory Volume | 19 | 2020 | 81 | 0.850 |
Why?
|
| Adult | 50 | 2021 | 9263 | 0.810 |
Why?
|
| Humans | 79 | 2021 | 32284 | 0.790 |
Why?
|
| Cluster Analysis | 6 | 2019 | 121 | 0.770 |
Why?
|
| Neutrophils | 5 | 2020 | 120 | 0.760 |
Why?
|
| Adolescent | 29 | 2020 | 3521 | 0.720 |
Why?
|
| Male | 56 | 2021 | 19434 | 0.700 |
Why?
|
| Female | 56 | 2021 | 19954 | 0.690 |
Why?
|
| Respiratory Function Tests | 14 | 2021 | 93 | 0.670 |
Why?
|
| Dyspnea | 2 | 2019 | 32 | 0.630 |
Why?
|
| Middle Aged | 38 | 2021 | 11843 | 0.600 |
Why?
|
| Cough | 1 | 2019 | 19 | 0.590 |
Why?
|
| Biological Products | 1 | 2020 | 79 | 0.570 |
Why?
|
| Young Adult | 19 | 2020 | 2652 | 0.570 |
Why?
|
| Bronchi | 7 | 2021 | 34 | 0.560 |
Why?
|
| Leukocyte Count | 5 | 2020 | 46 | 0.540 |
Why?
|
| Hypersensitivity | 2 | 2017 | 24 | 0.520 |
Why?
|
| Glucocorticoids | 5 | 2020 | 146 | 0.520 |
Why?
|
| Albuterol | 6 | 2019 | 17 | 0.520 |
Why?
|
| Immunologic Factors | 1 | 2017 | 53 | 0.500 |
Why?
|
| Child | 22 | 2019 | 2446 | 0.490 |
Why?
|
| Immunotherapy | 1 | 2017 | 91 | 0.490 |
Why?
|
| Smoking | 2 | 2021 | 505 | 0.490 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2020 | 59 | 0.470 |
Why?
|
| Administration, Inhalation | 11 | 2019 | 43 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 1052 | 0.440 |
Why?
|
| Immunoglobulin E | 8 | 2020 | 36 | 0.430 |
Why?
|
| Cohort Studies | 13 | 2021 | 1840 | 0.410 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2019 | 25 | 0.370 |
Why?
|
| Aged | 19 | 2021 | 10257 | 0.360 |
Why?
|
| Granulocytes | 3 | 2021 | 11 | 0.350 |
Why?
|
| European Continental Ancestry Group | 9 | 2019 | 1076 | 0.350 |
Why?
|
| Nitric Oxide | 7 | 2019 | 119 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 394 | 0.310 |
Why?
|
| Alendronate | 2 | 2019 | 10 | 0.290 |
Why?
|
| Epithelial Cells | 3 | 2019 | 137 | 0.280 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 543 | 0.280 |
Why?
|
| Inflammation | 4 | 2021 | 500 | 0.280 |
Why?
|
| African Americans | 8 | 2019 | 1335 | 0.280 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2019 | 31 | 0.260 |
Why?
|
| Gene Expression | 3 | 2021 | 345 | 0.260 |
Why?
|
| Cytokines | 2 | 2020 | 236 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 760 | 0.250 |
Why?
|
| Age of Onset | 4 | 2012 | 91 | 0.250 |
Why?
|
| Interleukin-5 | 2 | 2020 | 7 | 0.240 |
Why?
|
| Comorbidity | 5 | 2019 | 563 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2019 | 858 | 0.230 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 16 | 0.220 |
Why?
|
| Disease Progression | 2 | 2017 | 590 | 0.220 |
Why?
|
| Age Factors | 5 | 2017 | 1179 | 0.210 |
Why?
|
| Breath Tests | 6 | 2019 | 18 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 3896 | 0.210 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 13 | 0.210 |
Why?
|
| United States | 11 | 2019 | 4079 | 0.190 |
Why?
|
| Sex Factors | 2 | 2018 | 656 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2019 | 2320 | 0.180 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 5 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 312 | 0.180 |
Why?
|
| Double-Blind Method | 7 | 2019 | 566 | 0.180 |
Why?
|
| Vital Capacity | 4 | 2020 | 37 | 0.180 |
Why?
|
| Arginine | 2 | 2012 | 23 | 0.160 |
Why?
|
| Drug Resistance | 2 | 2020 | 42 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2019 | 222 | 0.160 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2020 | 23 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2019 | 716 | 0.160 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2020 | 1 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 44 | 0.160 |
Why?
|
| Progesterone Reductase | 1 | 2020 | 2 | 0.160 |
Why?
|
| Steroid Isomerases | 1 | 2020 | 2 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 59 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 158 | 0.150 |
Why?
|
| Multienzyme Complexes | 1 | 2020 | 19 | 0.150 |
Why?
|
| Obesity | 4 | 2021 | 1108 | 0.150 |
Why?
|
| Triamcinolone | 1 | 2019 | 12 | 0.150 |
Why?
|
| Aging | 2 | 2016 | 941 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 821 | 0.150 |
Why?
|
| Influenza Vaccines | 2 | 2010 | 82 | 0.150 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 23 | 0.150 |
Why?
|
| Respiration Disorders | 1 | 2019 | 7 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2019 | 34 | 0.150 |
Why?
|
| Influenza, Human | 2 | 2010 | 122 | 0.140 |
Why?
|
| Phosphoproteins | 1 | 2019 | 54 | 0.140 |
Why?
|
| Androstadienes | 2 | 2010 | 15 | 0.140 |
Why?
|
| Perioperative Nursing | 1 | 2018 | 2 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1485 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 40 | 0.130 |
Why?
|
| Death | 1 | 2018 | 51 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 213 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 88 | 0.130 |
Why?
|
| Prednisolone | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 7 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 478 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2019 | 1248 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 709 | 0.120 |
Why?
|
| Risk Factors | 5 | 2021 | 3938 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 55 | 0.120 |
Why?
|
| Cross-Over Studies | 4 | 2019 | 96 | 0.120 |
Why?
|
| Research | 1 | 2015 | 81 | 0.110 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 61 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 20 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 906 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 548 | 0.110 |
Why?
|
| Pregnenediones | 1 | 2014 | 1 | 0.100 |
Why?
|
| Cholecalciferol | 1 | 2014 | 25 | 0.100 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 6 | 0.100 |
Why?
|
| Bronchial Provocation Tests | 2 | 2011 | 6 | 0.100 |
Why?
|
| Vitamins | 1 | 2014 | 70 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 62 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 87 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 23 | 0.100 |
Why?
|
| Skin Tests | 3 | 2010 | 13 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 650 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 368 | 0.090 |
Why?
|
| Hispanic Americans | 3 | 2014 | 772 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 14 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2021 | 252 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 46 | 0.090 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 38 | 0.080 |
Why?
|
| Acetates | 1 | 2010 | 14 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1024 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2011 | 184 | 0.080 |
Why?
|
| Eosinophilia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 112 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 29 | 0.080 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2010 | 9 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 11 | 0.080 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 181 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 27 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2011 | 243 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 20 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 148 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 41 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 20 | 0.080 |
Why?
|
| Alleles | 2 | 2020 | 250 | 0.070 |
Why?
|
| Spirometry | 3 | 2019 | 25 | 0.070 |
Why?
|
| Vitamin D | 1 | 2010 | 186 | 0.070 |
Why?
|
| Biopsy | 2 | 2020 | 249 | 0.070 |
Why?
|
| Arginase | 1 | 2008 | 5 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3410 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 246 | 0.070 |
Why?
|
| Linear Models | 3 | 2018 | 426 | 0.070 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 3 | 0.070 |
Why?
|
| Airway Resistance | 1 | 2007 | 3 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 743 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 336 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 276 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 26 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 455 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2017 | 863 | 0.060 |
Why?
|
| Airway Obstruction | 1 | 2006 | 29 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 179 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 960 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 167 | 0.050 |
Why?
|
| Genotype | 2 | 2020 | 706 | 0.050 |
Why?
|
| Population Groups | 1 | 2004 | 8 | 0.050 |
Why?
|
| Ethnic Groups | 1 | 2007 | 450 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 22 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1073 | 0.050 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 16 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 10 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 149 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 164 | 0.050 |
Why?
|
| Mice | 1 | 2008 | 2544 | 0.050 |
Why?
|
| African Continental Ancestry Group | 1 | 2003 | 338 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 63 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 140 | 0.040 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Haplotypes | 3 | 2006 | 213 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 30 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2019 | 11 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 293 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 30 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 54 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 102 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 56 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 17 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 15 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 58 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 101 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 29 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 263 | 0.030 |
Why?
|
| Quality of Life | 2 | 2016 | 971 | 0.030 |
Why?
|
| Puberty | 1 | 2018 | 8 | 0.030 |
Why?
|
| Family | 1 | 2018 | 112 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 160 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 821 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 3 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 19 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 205 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 174 | 0.030 |
Why?
|
| Animals | 1 | 2008 | 8165 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 157 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 287 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 55 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Education | 1 | 2015 | 31 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 153 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 129 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 444 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 195 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 502 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 201 | 0.020 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 4 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1159 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 427 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 15 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 29 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 169 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 77 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 5 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3612 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 41 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 31 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 3 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 476 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 2 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 60 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 67 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 78 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 83 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 151 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 96 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 156 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 21 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 2 | 0.020 |
Why?
|
| London | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 4 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 85 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 189 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 256 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 29 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 135 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 2196 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 544 | 0.010 |
Why?
|
| Netherlands | 1 | 2003 | 25 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 212 | 0.010 |
Why?
|